Allos' Folotyn and Gloucster's Istodax: Exceptions That Prove The Rule?
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC continues to emphasize the importance of randomized controlled trials while supporting approval for two t-cell lymphoma drugs that conducted only singe-arm studies.